Friday, November 30, 2018 6:44:58 PM
trade,
“The Media will not be able to ignore an approval, even if it’s not the FDA and the stories will gain World Wide attention.”
Yes.
“I can wait for those and all of the noise we've had to put up with will flow like water off a ducks back”
Yes, yes.
trade,
AD will be approved based on extension results, as will Rett - that’s my call and I’m sticking to it.
And, I strongly agree with you, once PDD trial shows results, and the original AD strong responders are shown to media for government and unbelievable public approval, BP gets to be this guy:
“Guitar groups are on their way out, Mr Epstein." With that airy dismissal of the Beatles, supposedly directed over 50 years ago at the group's manager Brian Epstein, Dick Rowe of Decca made himself unwittingly but enduringly synonymous with catastrophic commercial misjudgements.
Big ouch! I can wait:)
Note: Dick Rowe was an “industry expert”. On the bright side, he became famous! (Bet you can’t name the guy who actually signed the Fab 4? No one can. Haha!)
Tunnel vision happens, resulting in Epic fails! (red herring pun - Beatles never recorded with Epic!)
Nice post. Great weekend - go listen to some White or Abbey Road,
Bio
“The Media will not be able to ignore an approval, even if it’s not the FDA and the stories will gain World Wide attention.”
Yes.
“I can wait for those and all of the noise we've had to put up with will flow like water off a ducks back”
Yes, yes.
trade,
AD will be approved based on extension results, as will Rett - that’s my call and I’m sticking to it.
And, I strongly agree with you, once PDD trial shows results, and the original AD strong responders are shown to media for government and unbelievable public approval, BP gets to be this guy:
“Guitar groups are on their way out, Mr Epstein." With that airy dismissal of the Beatles, supposedly directed over 50 years ago at the group's manager Brian Epstein, Dick Rowe of Decca made himself unwittingly but enduringly synonymous with catastrophic commercial misjudgements.
Big ouch! I can wait:)
Note: Dick Rowe was an “industry expert”. On the bright side, he became famous! (Bet you can’t name the guy who actually signed the Fab 4? No one can. Haha!)
Tunnel vision happens, resulting in Epic fails! (red herring pun - Beatles never recorded with Epic!)
Nice post. Great weekend - go listen to some White or Abbey Road,
Bio
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
